title: Hepatitis B Virus Reactivation Following Salazosulfapyridine Monotherapy in a Patient with Rheumatoid Arthritis.
abstract: A 72-year-old man was diagnosed with rheumatoid arthritis (RA) and prior hepatitis B virus (HBV) infection. He began treatment with salazosulfapyridine (SASP). Several months later, his blood tests reflected a slightly elevated liver function. Serum tests were positive for hepatitis B surface antigen and HBV-DNA, and the diagnosis of de novo HBV hepatitis was made. A genetic analysis showed that he had polymorphisms of ABCG2 and NAT2, which could lead to high plasma concentrations of SASP and sulfapyridine. To the best of our knowledge, this is the first report of de novo hepatitis developing during SASP monotherapy for RA.
authors.affiliation: Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Japan.
authors.forename: Kengo
authors.initials: K
authors.lastname: Akashi
authors.forename: Jun
authors.initials: J
authors.lastname: Saegusa
authors.forename: Yuji
authors.initials: Y
authors.lastname: Nakamachi
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakazawa
authors.forename: Shunichi
authors.initials: S
authors.lastname: Kumagai
authors.forename: Akio
authors.initials: A
authors.lastname: Morinobu
mesh_terms: D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004279:DNA, Viral; D006509:Hepatitis B / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects*; D006801:Humans; D008297:Male; D012460:Sulfasalazine / Q000009:adverse effects* / Q000627:therapeutic use; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D018501:Antirheumatic Agents; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D012460:Sulfasalazine